rSj26-Sj32-IgG4-ELISA法用于慢性日本血吸虫病疗效考核价值的研究  

Study on Therapeutic Evaluation of Chronic Schistosomiasis by rSj26-Sj32-IgG4-ELISA

作　　者：蔡世飞[1] 李文桂[1] 王敏[1] 周必英[1] 

机构地区：[1]重庆医科大学附属第一医院传染病寄生虫病研究所,重庆400016

出　　处：《热带医学杂志》2010年第10期1160-1162,1211,共4页Journal of Tropical Medicine

基　　金：重庆市科委地方病重大专项基金(No.2008AB5055;2008AB5008;2008AB5054)

摘　　要：目的 探讨rSj26-Sj32-IgG4-ELISA法用于慢性日本血吸虫病疗效考核价值的研究。方法 采用rSj26-Sj32融合蛋白和日本血吸虫成虫粗抗原(SjAWA)作为包被抗原建立ELISA方法检测慢性日本血吸虫病患者体内治疗前后血清中特异性IgG4抗体水平的变化。结果 rSj26-Sj32融合蛋白组中,化疗前、化疗后3个月、化疗后6个月和化疗后12个月血清中IgG4抗体阳性率分别为95.00%、77.27%、60.00%和30.43%;而SjAWA组中血清特异性IgG4抗体阳性率分别为97.50%、81.82%、55.00%和34.78%。结论 rSj26-Sj32-IgG4-ELISA法可用于慢性日本血吸虫病的疗效考核。Objective To study the therapeutic evaluation of chronic schistosomiasis by rSj26-Sj32-IgG4-ELISA.Methods Sj26-Sj32 and SjAWA specific IgG4 antibody levels were detected by ELISA.Results The positive rates of serum anti-Sj26-Sj32 IgG4 before,3 months,6 months and 12 months after therapy were 95.00%,77.27%,60.00% and 30.43%,respectively,while the positive rates of serum anti-SjAWA IgG4 were 97.50%,81.82%,55.00% and 34.78%,respectively.Conclusion The rSj26-Sj32-IgG4-ELISA may be useful for therapeutic evaluation for chronic schistosomiasis.

关 键 词：ELISA rSj26-Sj32融合蛋白 疗效考核 IGG4 

分 类 号：R532.21[医药卫生—内科学]